PROTHIPENDYL

First approved in 1960

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H19N3S
Molecular Weight	285.407
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCCN1C2=C(SC3=C1N=CC=C3)C=CC=C2

InChI

InChIKey=JTTAUPUMOLRVRA-UHFFFAOYSA-N

InChI=1S/C16H19N3S/c1-18(2)11-6-12-19-13-7-3-4-8-14(13)20-15-9-5-10-17-16(15)19/h3-5,7-10H,6,11-12H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C16H19N3S
Molecular Weight	285.407
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/mesh/67069248 | https://pubchem.ncbi.nlm.nih.gov/compound/14670

PROTHIPENDYL is a neuroleptic azaphenothiazine used to treat anxiety and agitation in psychotic syndromes. It also shows strong antihistamine and anti-emetic actions.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D1 receptor 101 Target ID: CHEMBL265 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7894260	Antagonist 2778
Dopamine D2 receptor 297 Target ID: CHEMBL339 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7894260\|https://books.google.ru/books?id=nXxZDwAAQBAJ&pg=PT456&lpg=PT456&dq=PROTHIPENDYL retrieved from The SAGE Encyclopedia of Pharmacology and Society edited by Sarah E. Boslaugh	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Tranquilizer 4 Sources: http://www.cdsco.nic.in/writereaddata/1961-1970.pdf	Primary		Approved 8429	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
18 ng/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1002/dta.2319	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PROTHIPENDYL serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
42.6 ng/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1002/dta.2319	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:		PROTHIPENDYL serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.5 h OTHER https://link.springer.com/chapter/10.1007%2F978-3-642-25761-2_10	unknown, oral		PROTHIPENDYL unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1280 mg 1 times / day multiple, oral Studied dose Dose: 1280 mg, 1 times / day Route: oral Route: multiple Dose: 1280 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5325240	unhealthy, 20 years (range: 16-31 years) n = 10 Health Status: unhealthy Condition: long-standing behaviour disorders Age Group: 20 years (range: 16-31 years) Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/5325240	Sources: https://pubmed.ncbi.nlm.nih.gov/5325240
960 mg 1 times / day multiple, oral Studied dose Dose: 960 mg, 1 times / day Route: oral Route: multiple Dose: 960 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5325240	unhealthy, 26 years (range: 14-42 years) n = 10 Health Status: unhealthy Condition: long-standing behaviour disorders Age Group: 26 years (range: 14-42 years) Sex: F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/5325240	Sources: https://pubmed.ncbi.nlm.nih.gov/5325240
4 g single, oral Overdose Dose: 4 g Route: oral Route: single Dose: 4 g Sources: https://pubmed.ncbi.nlm.nih.gov/7915105	unknown Health Status: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/7915105	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/7915105

AEs

AE	Significance	Dose	Population
Adverse event	grade 5	4 g single, oral Overdose Dose: 4 g Route: oral Route: single Dose: 4 g Sources: https://pubmed.ncbi.nlm.nih.gov/7915105	unknown Health Status: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/7915105

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	substrate 1037	substrate 1217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP1A2 1054 CYP2C19 991

Drug as victim

Target	Modality	Activity
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28756170/	likely
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28756170/	major
CYP2C19 991	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28756170/	major
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28756170/	minor
CYP3A4 1737	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28756170/	minor

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY547352	https://www.001chemical.com/chem/303-69-5
ABI Chem	AC1L24BL
BOC Sciences	303-69-5
Chemieliva Pharmaceutical Co., Ltd	PBCM1267030
Compound Cloud	14669
Compound Cloud	14670
HongKong Chemhere	SCE25807
Molcore	MC547352	https://www.molcore.com/product/303-69-5
MuseChem	R047529
NovoSeek	14670
Smolecule	S540442	http://www.smolecule.com/products/s540442
THE BioTek	bt-280854	https://www.thebiotek.com/product/inhibitors/bt-280854
Toronto Research Chemicals	C427943
Toronto Research Chemicals	P838850
ZINC	ZINC000000001996	http://zinc15.docking.org/substances/ZINC000000001996
eMolecules	110024654
eMolecules	300468680
eMolecules	31593248

PubMed

Title	Date	PubMed
Increased D-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study.	2009 Dec	19823762

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:28:10 UTC 2023` Edited by `admin` on `Fri Dec 15 15:28:10 UTC 2023`
Record UNII	5O6VWA87VA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PROTHIPENDYL

Official Name

English

PROTHIPENDYL [MI]

Common Name

English

prothipendyl [INN]

Common Name

English

Prothipendyl [WHO-DD]

Common Name

English

N,N-DIMETHYL-10H-PYRIDO(3,2-B)(1,4)BENZOTHIAZINE-10-PROPANAMINE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29710